We aimed to identify how often AE is associated with angiotensin-converting enzyme inhibitor
(ACEI-AE) therapy and whether the severity of AE episodes in these patients differs from the severity of idiopathic AE.
An evaluation of risk factors foe adverse drug events associated with angiotensin-converting enzyme inhibitors
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor
Correction page 245-250/Duzeltme sayfa 245-250: The effects of chronic usage of angiotensin-converting enzyme inhibitors
and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients Nezihi Baris, Ebru Ozpelit, Nazile Bilgin Dogan, Hande Kangul, Sefa Gul, Bahri Akdeniz, Sema Guneri
We will unlock new 3-D information for glycocerebrosidase 2 (GBA2) and use these together with GBA1 to design and exploit novel and specific enzyme inhibitors
as mechanistic and cellular probes, novel chaperones and imaging agents.
One group received calcium channel blockers (CCBs), and the other group received angiotensin converting enzyme inhibitors
(ACEIs) daily for duration of 6 months from the day of enrolment during the one year study period.
An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors
The researchers studied eight treatment classes, including angiotensin-converting enzyme inhibitors
, angiotensin II receptor blockers, [beta]-blockers, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and thiazide diuretics.
Are angiotensin-converting enzyme inhibitors
effective in decreasing mortality and morbidity in patients with heart disease but without heart failure or systolic dysfunction?
Evaluation of Enzyme Inhibitors
in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists.
Previous use of erythromycin in patients taking the enzyme inhibitors
was also checked, and was not a problem.